Fused Three-Ring PRMT5 Inhibitors Targeting the MTA-Bound State
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PRMT5 inhibitors are not selective enough to target MTAP-deleted tumor cells without affecting normal cells, leading to significant side effects, and there is a need for a novel strategy to selectively inhibit PRMT5 in these tumor cells.
Innovation Solution
Development of nitrogen-containing fused three-ring PRMT5 inhibitors that are designed to target PRMT5 only in the MTA-bound state, which is enriched in MTAP-deleted tumor cells, thereby minimizing effects on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 is inhibited in normal tissues, then therapeutic effect is achieved, but significant side effects occur (cytopenia, infertility, decreased skeletal muscle, myocardial hypertrophy)
Solution Approach 1:
The patent applies local quality by designing PRMT5 inhibitors that selectively target MTAP-deleted tumor cells through exploitation of the metabolic vulnerability created by MTAP deletion. The compounds preferentially inhibit PRMT5 in cells lacking MTAP while sparing normal cells with intact MTAP, thereby achieving localized therapeutic effect with reduced systemic toxicity. This is accomplished through the specific molecular structure of the inhibitors that recognizes and binds to the MTA-PRMT5 complex formed in MTAP-deleted cells.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure parameters of PRMT5 inhibitors to enhance their selectivity for MTAP-deleted tumor cells. The molecular structure is optimized to recognize the altered metabolic state (elevated MTA levels) in these cells, changing the binding affinity and selectivity parameters of the inhibitor to achieve preferential inhibition in the target cell population while reducing off-target effects in normal tissues.
2Reliability
If existing PRMT5 inhibitors are used, then PRMT5 inhibition is achieved, but selectivity for MTAP-deleted tumor cells is insufficient
Solution Approach 1:
The patent introduces MTA as an intermediary that mediates the selective inhibition of PRMT5 in MTAP-deleted tumor cells. The MTA-PRMT5 complex serves as the intermediate target that the inhibitors recognize and bind to with high affinity. This intermediary mechanism allows the inhibitors to distinguish between tumor cells (with elevated MTA) and normal cells (with low MTA), thereby achieving enhanced selectivity while maintaining effective PRMT5 inhibition in the target population.
3Adaptability or versatility
If broad PRMT5 inhibition is applied, then comprehensive therapeutic coverage is achieved, but treatment window is narrowed due to side effects
Solution Approach 1:
The patent applies segmentation by dividing the PRMT5 inhibition effect into two distinct populations: selective inhibition in MTAP-deleted tumor cells and sparing of normal cells with intact MTAP. This segmentation is achieved through the metabolic dependency of tumor cells on PRMT5 due to MTAP deletion, creating a natural division that allows comprehensive therapeutic coverage of the target population while preserving normal tissue function, thereby expanding the treatment window.
Data Source
AI summary
A PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, the use thereof as a PRMT5 inhibitor, and the use thereof in the treatment and/or prevention of PRMT5-mediated diseases.